Pollofex 120 mg or 180 mg FC tablets
PDF Leaflet Revision Date: 29 November 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Relief of symptoms associated with seasonal allergic rhinitis and chronic idiopathic urticaria.
Dosage (summary)
Adults: 120 mg daily for SAR, 180 mg daily for CIU.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not established; avoid during pregnancy and lactation.
Key Drug Interactions
- P-glycoprotein inhibitors
- Erythromycin
- Ketoconazole
- Antacids containing aluminium and magnesium
Contraindications
- Hypersensitivity to fexofenadine or excipients
Common side effects
- Headaches
- Drowsiness
- Dizziness
- Nausea
- Fatigue
Counselling Points
- May cause sedation in some individuals
- Avoid alcohol and CNS depressants
Serious warnings
- Caution in cardiovascular disease
- Limited data in elderly and impaired patients
Important Disclaimer
The Pollofex 120 mg or 180 mg FC tablets professional information leaflet below is the property of Biotech Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
